Denis Chem Lab [DENISCHEM] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison
Denis Chem Lab
BSE
Loading...
Sun Pharmaceutical
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Denis Chem Lab wins in 8 metrics, Sun Pharmaceutical wins in 11 metrics, with 0 ties. Sun Pharmaceutical appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Denis Chem Lab | Sun Pharmaceutical | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 15.50 | 36.74 | Denis Chem Lab |
| Price-to-Book Ratio | 1.56 | 5.30 | Denis Chem Lab |
| Debt-to-Equity Ratio | 0.01 | 3.26 | Denis Chem Lab |
| PEG Ratio | 0.83 | -1.89 | Sun Pharmaceutical |
| EV/EBITDA | 7.17 | 23.33 | Denis Chem Lab |
| Profit Margin (TTM) | 43.34% | 19.29% | Denis Chem Lab |
| Operating Margin (TTM) | 6.45% | 24.34% | Sun Pharmaceutical |
| EBITDA Margin (TTM) | 6.45% | 24.34% | Sun Pharmaceutical |
| Return on Equity | 9.49% | 15.08% | Sun Pharmaceutical |
| Return on Assets (TTM) | 7.19% | 11.87% | Sun Pharmaceutical |
| Free Cash Flow (TTM) | $44.64M | $119.44B | Sun Pharmaceutical |
| Dividend Yield | 4.03% | 1.26% | Denis Chem Lab |
| 1-Year Return | -37.30% | -14.60% | Sun Pharmaceutical |
| Price-to-Sales Ratio (TTM) | 0.79 | 7.11 | Denis Chem Lab |
| Enterprise Value | $1.36B | $3,578.34B | Sun Pharmaceutical |
| EV/Revenue Ratio | 0.79 | 6.65 | Denis Chem Lab |
| Gross Profit Margin (TTM) | 43.24% | 79.58% | Sun Pharmaceutical |
| Revenue per Share (TTM) | $125 | $224 | Sun Pharmaceutical |
| Earnings per Share (Diluted) | $6.10 | $43.39 | Sun Pharmaceutical |
| Beta (Stock Volatility) | N/A | 0.31 | N/A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Denis Chem Lab vs Sun Pharmaceutical Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Denis Chem Lab | 1.25% | 1.53% | -3.09% | -4.63% | -0.83% | -43.99% |
| Sun Pharmaceutical | -0.31% | 2.80% | 3.33% | -2.89% | -7.84% | -13.69% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Denis Chem Lab | -37.30% | 18.43% | 136.13% | 102.17% | 314.68% | 314.68% |
| Sun Pharmaceutical | -14.60% | 70.78% | 218.03% | 80.00% | 690.16% | 2,608.73% |
News Based Sentiment: Denis Chem Lab vs Sun Pharmaceutical
Denis Chem Lab
News based Sentiment: NEGATIVE
September was a challenging month for Denis Chem Lab, marked by continued stock underperformance and declining profitability ratios despite standard corporate governance events like the AGM and dividend approval. While not a crisis, the lack of positive catalysts and ongoing negative trends create a concerning investment picture.
Sun Pharmaceutical
News based Sentiment: MIXED
October was a mixed month for Sun Pharma, with a significant acquisition balanced against a decline in net profit. Positive analyst ratings and tariff news provide offsetting positive signals, making it a month of notable, but not overwhelmingly positive, developments for investors.
Performance & Financial Health Analysis: Denis Chem Lab vs Sun Pharmaceutical
| Metric | DENISCHEM | SUNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.36B | ₹3.92T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 5,862 | 2,839,112 |
| 90 Day Avg. Volume | 7,716 | 2,655,594 |
| Last Close | ₹95.75 | ₹1,631.20 |
| 52 Week Range | ₹87.99 - ₹180.00 | ₹1,548.00 - ₹1,952.25 |
| % from 52W High | -46.81% | -16.45% |
| All-Time High | ₹232.90 (Jun 17, 2024) | ₹1,960.35 (Sep 30, 2024) |
| % from All-Time High | -58.89% | -16.79% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | 0.10% |
| Quarterly Earnings Growth | 0.05% | -0.20% |
| Financial Health | ||
| Profit Margin (TTM) | 0.43% | 0.19% |
| Operating Margin (TTM) | 0.06% | 0.24% |
| Return on Equity (TTM) | 0.09% | 0.15% |
| Debt to Equity (MRQ) | 0.01 | 3.26 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹61.21 | ₹300.99 |
| Cash per Share (MRQ) | ₹0.61 | ₹108.88 |
| Operating Cash Flow (TTM) | ₹105.01M | ₹110.84B |
| Levered Free Cash Flow (TTM) | ₹80.76M | ₹109.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | 4.03% | 1.26% |
| Last 12-Month Dividend | ₹4.00 | ₹21.00 |
Valuation & Enterprise Metrics Analysis: Denis Chem Lab vs Sun Pharmaceutical
| Metric | DENISCHEM | SUNPHARMA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 15.50 | 36.74 |
| Forward P/E | N/A | 48.79 |
| PEG Ratio | 0.83 | -1.89 |
| Price to Sales (TTM) | 0.79 | 7.11 |
| Price to Book (MRQ) | 1.56 | 5.30 |
| Market Capitalization | ||
| Market Capitalization | ₹1.36B | ₹3.92T |
| Enterprise Value | ₹1.36B | ₹3.58T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.79 | 6.65 |
| Enterprise to EBITDA | 7.17 | 23.33 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.31 |
| Book Value per Share (MRQ) | ₹61.21 | ₹300.99 |
Financial Statements Comparison: Denis Chem Lab vs Sun Pharmaceutical
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | DENISCHEM | SUNPHARMA |
|---|---|---|
| Revenue/Sales | ₹432.76M | ₹137.86B |
| Cost of Goods Sold | ₹245.65M | ₹28.15B |
| Gross Profit | ₹187.11M | ₹109.71B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹32.00M | ₹33.72B |
| EBITDA | ₹51.13M | ₹47.66B |
| Pre-Tax Income | ₹33.15M | ₹31.73B |
| Income Tax | ₹8.40M | ₹8.70B |
| Net Income (Profit) | ₹24.75M | ₹22.93B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | DENISCHEM | SUNPHARMA |
|---|---|---|
| Cash & Equivalents | ₹8.50M | ₹102.69B |
| Total Current Assets | ₹706.45M | ₹526.24B |
| Total Current Liabilities | ₹261.73M | ₹181.94B |
| Long-Term Debt | ₹4.53M | ₹3.58B |
| Total Shareholders Equity | ₹851.04M | ₹724.86B |
| Retained Earnings | ₹390.31M | ₹578.62B |
| Property, Plant & Equipment | ₹39.91M | ₹100.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | DENISCHEM | SUNPHARMA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | DENISCHEM | SUNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 5,862 | 2,839,112 |
| Average Daily Volume (90 Day) | 7,716 | 2,655,594 |
| Shares Outstanding | 13.88M | 2.40B |
| Float Shares | N/A | 1.04B |
| % Held by Insiders | 0.79% | 0.56% |
| % Held by Institutions | 0.00% | 0.25% |
Dividend Analysis & Yield Comparison: Denis Chem Lab vs Sun Pharmaceutical
| Metric | DENISCHEM | SUNPHARMA |
|---|---|---|
| Last 12-Month Dividend | ₹4.00 | ₹21.00 |
| Last 12-Month Dividend Yield | 4.03% | 1.26% |
| 3-Year Avg Annual Dividend | ₹3.67 | ₹14.67 |
| 3-Year Avg Dividend Yield | 1.73% | 0.46% |
| 3-Year Total Dividends | ₹11.00 | ₹44.00 |
| Ex-Dividend Date | Sep 19, 2025 | Jul 07, 2025 |